[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334029-105":59,"doc-detail-334029-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","targeting-cdcp1-boost-cd8-t-cells-mediated-cytotoxicity-in-cervical-cancer-via-the-jak-stat-signaling-pathway","Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK-STAT signaling pathway","","Cervical cancer remains a global health challenge, and new immunotherapeutic targets are needed to improve outcomes. This study investigates CUB domain-containing protein 1 (CDCP1) in cervical cancer progression and evaluates its therapeutic potential. Analyses in patient cohorts and preclinical models assess links between CDCP1 expression and prognosis, and examine effects on tumor-infiltrating T cells and the JAK/STAT pathway, including CTLs and Tregs. Findings show CDCP1 overexpression correlates with poor prognosis and that CDCP1 inhibition suppresses tumor growth while enhancing antitumor immunity.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-cdcp1-boost-cd8-t-cells-mediated-cytotoxicity-in-cervical-cancer-via-the-jak-stat-signaling-pathway/334029/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-cdcp1-boost-cd8-t-cells-mediated-cytotoxicity-in-cervical-cancer-via-the-jak-stat-signaling-pathway/334029.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main goal regarding CDCP1 in cervical cancer?","Question",{"text":112,"@type":113},"The study aims to determine CDCP1’s role in cervical cancer progression and assess whether CDCP1 could serve as a therapeutic target for immunotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CDCP1 affect T cells according to the study?",{"text":117,"@type":113},"CDCP1 overexpression is linked to poor prognosis and affects tumor-infiltrating T cells by influencing the activity of cytotoxic T lymphocytes (CTLs) and regulatory T cells (Tregs).",{"name":119,"@type":110,"acceptedAnswer":120},"What is the proposed mechanism involving JAK/STAT signaling?",{"text":121,"@type":113},"CDCP1 binds to CD6 on T cells and inhibits the JAK-STAT signaling pathway, thereby modulating immune responses in cervical cancer.",{"name":123,"@type":110,"acceptedAnswer":124},"What therapeutic effect was observed when targeting CDCP1?",{"text":125,"@type":113},"Using the CDCP1 inhibitor 8-prenylnaringenin (8PN) suppresses tumor growth in vivo and enhances antitumor immunity.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},334029,1790194590,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Original research  \nTargeting CDCP1 boost CD8+ T cellsmediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway  \nHua Huang  ,1,2 Yuwen Pan,1,2 Qiuwen Mai,1,2 Chunyu Zhang,1,2 Qiqiao Du  ,1,2 Yuandong Liao,1,2 Shuhang Qin,1,2 Yili Chen,1,2 Jiaming Huang,1,2 Jie Li,1,2 Tianyu Liu,1,2 Qiaojian Zou,1,2 Yijia Zhou,1,2 Li Yuan,1,2 Wei Wang,1,2  \nYanchun Liang,1,2 Chao Yun Pan,3 Junxiu Liu  ,1,2 Shuzhong Yao1,2  \nTo cite: Huang H, Pan Y, Mai Q, et al. Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway. Journal for ImmunoTherapy of Cancer 2024;12:e009416 . doi:10 . 1136/ jitc-2024-009416  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-009416](jitc-2024-009416)) .  \nHH, YP and QM contributed equally.  \nAccepted 10 October 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \n1Department of Obstetricsand Gynecology, Sun Yatsen University First Affiliated Hospital, Guangzhou, Guangdong, China 2Guangdong Provincial Clinical Research Center for Obstetrical and Gynecological Diseases, Guangzhou, Guangdong, China 3Department of Biochemistry, Sun Yat-Sen University, Guangzhou, Guangdong, China  \nCorrespondence to  \nDr Shuzhong Yao;  \n[yaoshuzh@mail.sysu.edu.cn](yaoshuzh@mail.sysu.edu.cn)  \nDr Junxiu Liu;  \n[liujxiu@mail.sysu.edu.cn](liujxiu@mail.sysu.edu.cn)  \nABSTRACT  \nBackground Cervical cancer remains a global health challenge. The identification of new immunotherapeutic targets may provide a promising platform for advancing cervical cancer treatment.  \nObjective This study aims to investigate the role of CUB domain-containing protein 1 (CDCP1) in cervical cancer progression and evaluate its potential as a therapeutic target.  \nMethods We performed comprehensive analyses  \nusing patient cohorts and preclinical models to examine the association between CDCP1 expression and cervical cancer prognosis. Then in immunodeficient and immunocompetent mouse models, we further investigated the impact of CDCP1 on the tumor immune microenvironment, focusing on its effects on tumorinfiltrating T cells, including cytotoxic T lymphocytes (CTLs) and regulatory T cells (Tregs) . Mechanistic studies were performed to elucidate the pathways involved in CDCP1-mediated immune modulation, in particular its interaction with the T cell receptor CD6 and the activation of the JAKSTAT signaling pathway.  \nResults Our results show that CDCP1 overexpression is associated with poor prognosis and T cell infliction in cervical cancer. Specifically, it affects the activity of CTLsand Tregs. Mechanistically, CDCP1 binds to CD6 and inhibits the JAK-STAT pathway of T cells. The study further demonstrates that targeting CDCP1 with the inhibitor 8-prenylnaringenin (8PN) effectively suppresses tumor growth in vivo and enhances antitumor immunity. Conclusions CDCP1 plays a critical role in cervical cancer progression by modulating the tumor immune microenvironment. Targeting CDCP1 offers a promising therapeutic strategy to improve the outcome of patients with cervical cancer.  \nINTRODUCTION  \nAffecting women worldwide, cervical cancer ranks fourth in both incidence and mortality among gynecological tumors.1 2 In 2022 alone, an estimated 604,000 new cases and 342,000 deaths were reported globally.3 The standard of care for cervical cancer includes surgery, radiotherapy, and chemotherapy.4 5 However, for patients with recurrent or metastatic  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ CDCP1 is highly expressed in various malignant tumors and can directly influence tumor cell invasion and metastasis through signaling pathways such as PI3K/Akt, PKC5, SRC, and ERK/MAPK. However, its interaction with immune cells remains unexplored.\u003Cbr>WHAT THIS STUDY A","cbCaivArhnXYOL2a","https://ap.wps.com/l/cbCaivArhnXYOL2a","pdf",12527254,17,"English","# Abstract\n## Background and Objective\n## Methods and Mechanistic Focus\n## Key Results and Conclusions","[{\"question\":\"What is the study’s main goal regarding CDCP1 in cervical cancer?\",\"answer\":\"The study aims to determine CDCP1’s role in cervical cancer progression and assess whether CDCP1 could serve as a therapeutic target for immunotherapy.\"},{\"question\":\"How does CDCP1 affect T cells according to the study?\",\"answer\":\"CDCP1 overexpression is linked to poor prognosis and affects tumor-infiltrating T cells by influencing the activity of cytotoxic T lymphocytes (CTLs) and regulatory T cells (Tregs).\"},{\"question\":\"What is the proposed mechanism involving JAK/STAT signaling?\",\"answer\":\"CDCP1 binds to CD6 on T cells and inhibits the JAK-STAT signaling pathway, thereby modulating immune responses in cervical cancer.\"},{\"question\":\"What therapeutic effect was observed when targeting CDCP1?\",\"answer\":\"Using the CDCP1 inhibitor 8-prenylnaringenin (8PN) suppresses tumor growth in vivo and enhances antitumor immunity.\"}]","Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK-STAT signaling pathway | PDF",1790005071,43]